Chronic lymphocytic leukemia
Citation, DOI, disclosures and article data
At the time the article was created Yuranga Weerakkody had no recorded disclosures.View Yuranga Weerakkody's current disclosures
Chronic lymphocytic leukemia (CLL) is a hematological malignancy characterized by the proliferation of mostly mature but abnormal leukocytes.
Chronic lymphocytic leukemia is considered the most common type of leukemia in the Western hemisphere; its prevalence in Europe and North America ranges from 29-38% of all leukaemias 1. It primarily affects adults 65-70 years of age 3.
The diagnosis is generally established by a bone marrow biopsy and immunophenotyping.
Up to half of the patients can be asymptomatic with the disease being incidentally discovered by routine blood workup 3. Patients may sometimes present with hepatomegaly, splenomegaly or both and/or hemolytic anemia.
It is a B-lineage neoplasm of prefollicular center cells that is usually associated with circulating neoplastic small lymphocytes. From a morphologic and immunophenotypic perspective, the malignant cells of chronic lymphocytic leukemia tend to be identical to those of nodal-based small lymphocytic lymphoma (SLL), and these two malignancies are thought to represent different manifestations of the same disease 1. This is reflected in the latest WHO classification of haematolymphoid tumors (5th edition).
There are two common staging systems in use which are:
As with other types of bone marrow infiltrative disease, it is possible to see a diffusely hypointense signal of bone structures on T1, easier to see on spinal MRI.
Treatment and prognosis
Chronic lymphocytic leukemia treatment is offered in the presence of active disease, which is characterized by any of the listed below 7:
presence of B symptoms
progressive bone marrow failure
extensive or rapidly progressing lymphadenopathy
massive or rapidly progressive splenomegaly
uncontrolled autoimmune cytopenias
rapid lymphocyte doubling time: either occurring in <6 months or when there is an increase of 50% in ≤2 months
About one-third of patients with chronic lymphocytic leukemia will never require treatment 7.